We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Retrospective analysis showed favorable safety profile of siponimod in patients with relapsing forms of multiple sclerosis, indicating support for its use.
This RW study confirmed favourable benefit-risk profile of siponimod in Chinese patients with RMS.
No takes yet. Share an insight, caveat, or question.
Min Cai (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: